Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  12/21/2011
 
Trade Name:  Isentress
 
Generic Name or Proper Name (*):  raltegravir
 
Indications Studied:  In combination with other antiretroviral agents for the treatment of HIV-1 infection
 
Label Changes Summary:  Isentress Chewable tablets: Expanded indication from adults to pediatric patients 2 - < 12 years and weighing at least 10kg Isentress Tablets: Expanded indication from adults to pediatric patients 6-18 years Safety and effectiveness in patients <2 years have not been establishedBecause the formulations are not bioequivalent, do not substitute chewable tablets for the 400 mg film-coated tablet Safety profile similar to that observed in adults Information on dosing, adverse reactions, clinical trial and PK parameters New dosage form
 
Product Labeling:  Labeling  Opens a new window
 
BPCA(B) and PREA(P):  B, P
 
Sponsor:  Merck
 
NNPS:  FALSE'
 
Therapeutic Category:  Antiviral
 
-
-